Markforged Holding Corp Warrants (17/08/2025) Bolsa (OTC: MKFGW)

Últimas noticias sobre Markforged Holding Corp Warrants (17/08/2025) (OTC:MKFGW) Bolsa

Markforged Holding Corp Warrants (17/08/2025)

<p>Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate of $0.02 by 150 percent. This is unchanged from the same period last year.  The company reported quarterly sales of $22.01 million which beat the analyst consensus estimate of $21.99 million by 0.08 percent.  This is a 8.30 percent increase over sales of $20.32 million the same period last year.</p>


Earnings

Earnings Beats

Earnings Misses

News

USIO

Usio Q1 EPS $(0.01) Misses $0.02 Estimate, Sales $22.01M Beat $21.99M Estimate

<p><strong>BiomX</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that BiomX will report an <strong>earnings per share</strong> (EPS) of $-0.30. </p>
<p>The announcement from BiomX is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<p>Here's a look at BiomX's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.91</td>
<td>-0.31</td>
<td>-0.7</td>
<td>-2.8</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-11.0%</td>
<td>-17.0%</td>
<td>-12.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<h3>Stock Performance</h3>
<p>Shares of BiomX were trading at $0.535 as of May 13. Over the last 52-week period, shares are down 83.44%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/PHGE/earnings"><strong>To track all earnings releases for BiomX visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


PHGE

A Look at BiomX's Upcoming Earnings Report

CORRECTION: Excelerate Energy Did Not Report Earnings Today

<p>TMC Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NASDAQ">TMC</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.03) by 100 percent. This is a 25 percent increase over losses of $(0.08) per share from the same period last year.</p>


TMC Metals Q1 EPS $(0.06) Misses $(0.03) Estimate

<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.trilinkbiotech.com%2F&amp;esheet=54254971&amp;newsitemid=20250514331075&amp;lan=en-US&amp;anchor=TriLink+BioTechnologies&amp;index=1&amp;md5=0931b801f9635fef0b90aeafdf9db435">TriLink BioTechnologies</a> (TriLink&#xAE;), a Maravai&#xAE; LifeSciences company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit international organization devoted to and the discovery, development and delivery of vaccines for global health signed a Memorandum of Understanding to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies.</p>
<p>According to the terms of the MOU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives.</p>
<p><br />&nbsp;</p>
<p><br />&nbsp;</p>


MRVI

TriLink and IVI Collaborate To Advance Research And Development Of mRNA-Based Vaccines And Promote Equitable Access To Essential Vaccines And Health Technologies

<p>Oncolytics Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCY#NASDAQ">ONCY</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.09) by 33.33 percent. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year.</p>


ONCY

Oncolytics Biotech Q1 EPS $(0.06) Beats $(0.09) Estimate

<p>Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $1.11 by 8.11 percent. This is a 17.81 percent decrease over earnings of $1.46 per share from the same period last year.  The company reported quarterly sales of $336.70 million which missed the analyst consensus estimate of $343.08 million by 1.86 percent.  This is a 7.84 percent decrease over sales of $365.35 million the same period last year.</p>


JACK

Jack In The Box Q2 Adj. EPS $1.20 Beats $1.11 Estimate, Sales $336.70M Miss $343.08M Estimate

<p>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) is gearing up to announce its quarterly earnings on Thursday, 2025-05-15. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Quantum Computing will report an <strong>earnings per share</strong> (EPS) of $-0.05.</p>
<p>The announcement from Quantum Computing is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.42, leading to a 0.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at Quantum Computing's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.05</td>
<td></td>
<td>-0.08</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.47</td>
<td>-0.06</td>
<td>-0.06</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>0.0%</td>
<td>25.0%</td>
<td>1.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Tracking Quantum Computing's Stock Performance</h3>
<p>Shares of Quantum Computing were trading at $8.79 as of May 13. Over the last 52-week period, shares are up 953.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Quantum Computing</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Quantum Computing.</p>
<p>Quantum Computing has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $14.0, the consensus suggests a potential 59.27% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Exodus Movement, Cipher Mining and Pagaya Techs, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Exodus Movement, with an average 1-year price target of $61.5, suggesting a potential 599.66% upside.</li>
<li>Analysts currently favor an Buy trajectory for Cipher Mining, with an average 1-year price target of $7.17, suggesting a potential 18.43% downside.</li>
<li>Analysts currently favor an Buy trajectory for Pagaya Techs, with an average 1-year price target of $27.6, suggesting a potential 213.99% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary presents essential metrics for Exodus Movement, Cipher Mining and Pagaya Techs, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantum Computing</td>
<td>Buy</td>
<td>-17.33%</td>
<td>$34K</td>
<td>-61.10%</td>
</tr>
<tr>
<td>Exodus Movement</td>
<td>Buy</td>
<td>148.45%</td>
<td>$32.80M</td>
<td>29.84%</td>
</tr>
<tr>
<td>Cipher Mining</td>
<td>Buy</td>
<td>1.71%</td>
<td>$19.76M</td>
<td>-5.50%</td>
</tr>
<tr>
<td>Pagaya Techs</td>
<td>Buy</td>
<td>19.28%</td>
<td>$115.62M</td>
<td>2.24%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Quantum Computing ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity.</p>
<h3>Delving into Quantum Computing's Background</h3>
<p>Quantum Computing Inc is an integrated photonics and quantum optics technology company that provides accessible and affordable quantum machines to the world today. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offer capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.</p>
<h3>Unraveling the Financial Story of Quantum Computing</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Quantum Computing's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-17.33%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Quantum Computing's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-82640.32%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Quantum Computing's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-61.1%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-44.48%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Quantum Computing's debt-to-equity ratio is below the industry average at <strong>0.01</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/QUBT/earnings"><strong>To track all earnings releases for Quantum Computing visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


QUBT

Quantum Computing's Earnings Outlook

<p>Red Cat Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) affirms FY2025 sales outlook from $80.00 million-$120.00 million to $80.00 million-$120.00 million vs $80.17 million estimate.</p>


Guidance

RCAT

Red Cat Holdings Affirms FY2025 Sales Guidance of $80.00M-$120.00M vs $80.17M Est

<p>Ibotta (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>) sees Q2 sales of $86.500 million-$92.500 million vs $89.15 million analyst estimate.</p>


IBTA

Ibotta Sees Q2 Sales $86.500M-$92.500M vs $89.15M Est

<p>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) reported quarterly sales of $6.50 million which beat the analyst consensus estimate of $6.23 million by 4.28 percent.  This is a 25.88 percent decrease over sales of $8.77 million the same period last year.</p>


BNGO

Bionano Genomics Q1 Sales $6.50M Beat $6.23M Estimate

<p>Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.86) by 5.81 percent. This is a 37.29 percent decrease over losses of $(0.59) per share from the same period last year.</p>


CELC

Celcuity Q1 Adj. EPS $(0.81) Beats $(0.86) Estimate

<p>Red Cat Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.08) by 237.5 percent. This is a 145.45 percent decrease over losses of $(0.11) per share from the same period last year.  The company reported quarterly sales of $1.63 million which missed the analyst consensus estimate of $3.85 million by 57.62 percent.  This is a 6.75 percent decrease over sales of $1.75 million the same period last year.</p>


Red Cat Holdings Q1 EPS $(0.27) Misses $(0.08) Estimate, Sales $1.63M Miss $3.85M Estimate

<p>Financial giants have made a conspicuous bullish move on Core Scientific. Our analysis of options history for Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) revealed 17 unusual trades.</p>
<p>Delving into the details, we found 58% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $700,927, and 14 were calls, valued at $593,613.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $6.0 and $17.0 for Core Scientific, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Core Scientific stands at 9455.15, with a total volume reaching 23,762.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Core Scientific, situated within the strike price corridor from $6.0 to $17.0, throughout the last 30 days.</p>
<h3>Core Scientific Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747252917_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CORZ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$7.15</td>
<td>$7.1</td>
<td>$7.15</td>
<td>$17.00</td>
<td>$643.5K</td>
<td>1.0K</td>
<td>900</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$1.85</td>
<td>$1.78</td>
<td>$1.84</td>
<td>$11.00</td>
<td>$92.0K</td>
<td>13.0K</td>
<td>509</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$0.68</td>
<td>$0.61</td>
<td>$0.67</td>
<td>$14.00</td>
<td>$67.0K</td>
<td>2.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1.18</td>
<td>$1.15</td>
<td>$1.15</td>
<td>$12.00</td>
<td>$57.3K</td>
<td>4.7K</td>
<td>501</td>
</tr>
<tr>
<td>CORZ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$2.16</td>
<td>$2.16</td>
<td>$2.16</td>
<td>$12.00</td>
<td>$54.0K</td>
<td>30.2K</td>
<td>250</td>
</tr>
</tbody>
</table>
</p>
<h3>About Core Scientific</h3>
<p>Core Scientific Inc is engaged in designing, building and operating digital infrastructure for high-performance computing. The business operates in three operating segments; Digital Asset Self-Mining, consisting of performing digital asset mining for the own account, Digital Asset Hosted Mining, consisting of providing hosting services to third parties for digital asset mining, and HPC Hosting, consisting of providing hosting services to third parties for graphics processing unit (GPU) based HPC hosting operations. The majority of revenue is derived from the Digital Asset Self-Mining Segment.</p>
<p>Following our analysis of the options activities associated with Core Scientific, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Core Scientific Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 11,555,852, the CORZ's price is down by -0.24%, now at $10.21. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 84 days.</li>
</ul>
<h3>What Analysts Are Saying About Core Scientific</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $16.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Oppenheimer has revised its rating downward to Outperform, adjusting the price target to $15.<br />
&#x2A; An analyst from Canaccord Genuity has decided to maintain their Buy rating on Core Scientific, which currently sits at a price target of $17. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Core Scientific with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

Core Scientific, Inc. - Class A Common Stock

CORZ

Unpacking the Latest Options Trading Trends in Core Scientific

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Citigroup</strong>.</p>
<p>Looking at options history for Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) we detected 18 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 44% with bearish.</p>
<p>From the overall spotted trades, 6 are puts, for a total amount of $383,306 and 12, calls, for a total amount of $1,205,708.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $87.5 for Citigroup over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Citigroup's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Citigroup's significant trades, within a strike price range of $60.0 to $87.5, over the past month.</p>
<h3>Citigroup Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747252912_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$12.8</td>
<td>$12.65</td>
<td>$12.65</td>
<td>$70.00</td>
<td>$417.4K</td>
<td>2.9K</td>
<td align="right">331</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$15.8</td>
<td>$15.65</td>
<td>$15.8</td>
<td>$70.00</td>
<td>$158.0K</td>
<td>1.2K</td>
<td align="right">0</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$13.35</td>
<td>$12.7</td>
<td>$12.8</td>
<td>$65.00</td>
<td>$130.5K</td>
<td>8.9K</td>
<td align="right">132</td>
</tr>
<tr>
<td>C</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$16.5</td>
<td>$16.3</td>
<td>$16.3</td>
<td>$87.50</td>
<td>$127.1K</td>
<td>45</td>
<td align="right">128</td>
</tr>
<tr>
<td>C</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$16.1</td>
<td>$15.75</td>
<td>$15.89</td>
<td>$70.00</td>
<td>$79.4K</td>
<td>1.2K</td>
<td align="right">150</td>
</tr>
</tbody>
</table>
</p>
<h3>About Citigroup</h3>
<p>Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.</p>
<p>Following our analysis of the options activities associated with Citigroup, we pivot to a closer look at the company's own performance.</p>
<h3>Citigroup's Current Market Status</h3>
<ul>
<li>With a volume of 8,054,245, the price of C is down -0.41% at $75.26. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 58 days.</li>
</ul>
<h3>Professional Analyst Ratings for Citigroup</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $84.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Citigroup with a target price of $78.<br />
&#x2A; Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Citigroup with a target price of $94.<br />
&#x2A; An analyst from Keefe, Bruyette &amp; Woods downgraded its action to Outperform with a price target of $92.<br />
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Citigroup with a target price of $79.<br />
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $77. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Citigroup options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Decoding Citigroup's Options Activity: What's the Big Picture?

<p>Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) has outperformed the market over the past 10 years by 5.6% on an annualized basis producing an average annual return of 16.26%. Currently, Sea has a market capitalization of $93.60 billion. </p>
<p><strong>Buying $100 In SE:</strong> If an investor had bought $100 of SE stock 10 years ago, it would be worth <strong>$445.55</strong> today based on a price of $158.10 for SE at the time of writing.</p>
<h3>Sea's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747252908_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

Here's How Much $100 Invested In Sea 10 Years Ago Would Be Worth Today

<p>Monogram Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 16.67 percent. This is a 9.09 percent increase over losses of $(0.11) per share from the same period last year.</p>


MGRM

Monogram Technologies Q1 EPS $(0.10) Beats $(0.12) Estimate

<p>Deep-pocketed investors have adopted a bullish approach towards Brunswick (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BC#NYSE">BC</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BC usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Brunswick. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 12% leaning bullish and 12% bearish. Among these notable options, 4 are puts, totaling $119,282, and 4 are calls, amounting to $196,692.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $55.0 for Brunswick over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Brunswick's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Brunswick's substantial trades, within a strike price spectrum from $45.0 to $55.0 over the preceding 30 days.</p>
<h3>Brunswick Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747252907_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$5.6</td>
<td>$4.8</td>
<td>$5.15</td>
<td>$55.00</td>
<td>$51.7K</td>
<td align="right">50</td>
<td align="right">363</td>
</tr>
<tr>
<td>BC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$5.5</td>
<td>$4.7</td>
<td>$5.4</td>
<td>$55.00</td>
<td>$51.1K</td>
<td align="right">50</td>
<td align="right">403</td>
</tr>
<tr>
<td>BC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$5.2</td>
<td>$4.7</td>
<td>$5.0</td>
<td>$55.00</td>
<td>$50.2K</td>
<td align="right">50</td>
<td align="right">878</td>
</tr>
<tr>
<td>BC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$5.3</td>
<td>$4.8</td>
<td>$5.05</td>
<td>$55.00</td>
<td>$43.5K</td>
<td align="right">50</td>
<td align="right">703</td>
</tr>
<tr>
<td>BC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$3.5</td>
<td>$2.7</td>
<td>$3.15</td>
<td>$45.00</td>
<td>$31.7K</td>
<td align="right">6</td>
<td align="right">363</td>
</tr>
</tbody>
</table>
</p>
<h3>About Brunswick</h3>
<p>Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns numerous Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.</p>
<p>Following our analysis of the options activities associated with Brunswick, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Brunswick</h3>
<ul>
<li>With a trading volume of 499,460, the price of BC is down by -0.21%, reaching $52.15.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 71 days from now.</li>
</ul>
<h3>Expert Opinions on Brunswick</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $51.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Jefferies persists with their Hold rating on Brunswick, maintaining a target price of $45.<br />
&#x2A; Maintaining their stance, an analyst from BMO Capital continues to hold a Outperform rating for Brunswick, targeting a price of $65.<br />
&#x2A; An analyst from DA Davidson has revised its rating downward to Neutral, adjusting the price target to $43. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Brunswick options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Looking At Brunswick's Recent Unusual Options Activity

<p>MDxHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) affirms FY2025 sales outlook from $108.00 million-$110.00 million to $108.00 million-$110.00 million.</p>


MDXH

MDxHealth Affirms FY2025 Sales Guidance of $108.00M-$110.00M

<p>During the last three months, 5 analysts shared their evaluations of MidCap Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIC#NASDAQ">MFIC</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for MidCap Financial, revealing an average target of $13.6, a high estimate of $15.00, and a low estimate of $11.50. This current average represents a 7.48% decrease from the previous average price target of $14.70. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747252892_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of MidCap Financial by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Melissa Wedel</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$13.50</td>
</tr>
<tr>
<td>Paul Johnson</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$14.50</td>
<td>$15.00</td>
</tr>
<tr>
<td>Finian O'Shea</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to MidCap Financial. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of MidCap Financial compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of MidCap Financial's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of MidCap Financial's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MFIC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on MidCap Financial analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering MidCap Financial: A Closer Look</h2>
<p>MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. Its investment objective is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.</p>
<h3>Breaking Down MidCap Financial's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Negative Revenue Trend:</strong> Examining MidCap Financial's financials over 3M reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-29.12%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> MidCap Financial's net margin excels beyond industry benchmarks, reaching <strong>90.38%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.71%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> MidCap Financial's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.75%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.25</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Markforged Holding Corp Warrants (17/08/2025)

Noticias

Últimas noticias sobre Markforged Holding Corp Warrants (17/08/2025) (OTC:MKFGW) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL